The Global Oligonucleotide API Industry is poised for a transformative journey, with a forecasted Compound Annual Growth Rate (CAGR) of 10.2% from 2022 to 2030. Fueled by escalating demand for innovative drug classes, this sector emerges as a beacon of promise within the pharmaceutical industry.
In a groundbreaking analysis by Future Market Insights (FMI), the Global Oligonucleotide API Industry is predicted to experience a substantial upswing, propelling its value from US$ 2.46 billion in 2022 to an impressive US$ 5.36 billion by the culmination of 2030. This remarkable trajectory not only signifies the industry’s vast potential but also underscores the escalating interest in oligonucleotides as a pivotal player in the pharmaceutical market.
FMI’s research indicates that the Oligonucleotide API landscape is currently brimming with activity, with over 100 oligonucleotide APIs advancing through various clinical trial phases, with regulatory approval on the horizon. This marks a pivotal moment for the industry, as it signifies that the demand for production capacity is poised to surge significantly post-approval. As a result, the Global Oligonucleotide API Industry is set to maintain its upward trajectory throughout the next decade.
Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-11933
Apart from immune therapy, microbial and cardiovascular infections, and cancer, oligonucleotide APIs are being tried out to treat neurological disorders like Alzheimer’s as well. However, factors like regulatory complexities and timely delivery of oligonucleotides (amidst COVID-19) are acting as restraints.
Key Takeaways from Global Oligonucleotide API Industry Study
- Antisense oligonucleotide APIs are anticipated to reach US$ 4 Bn by 2030.
- North America and Europe collectively accounted for more than 47% of revenue share in 2019 while Asia Pacific is expected to grow at the fastest rate in the forecast period.
- Increase in the use of antisense oligonucleotide APIs (especially post-approval from the US FDA in 2016) to boost the market in the forecast period
“Inorganic mode of growth coupled with broad therapeutic applications in gene therapy is expected to bolster the Global Oligonucleotide API Industry,” says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)
New Product Launches: Key Indicators to Global Oligonucleotide API Industry
FMI has analyzed players such as Akcea Therapeutics, Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., and Dynavax Technologies in this report. According to the analysis, these players are consolidating their positions through new product launches.
For instance –
- In March 2020, Dynavax entered into a collaboration with Clover Biopharmaceuticals to develop a vaccine candidate to combat COVID-19. Clover is into advanced evaluation of its Covid-19 S-Trimer, protein-based coronavirus vaccine candidate and Dynavax has its technical expertise along with proprietary toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018 for executing this.
- Alnylam Pharmaceuticals, Inc., in 2018, launched Givlaari and Onpattro at the commercial level.
Ignite Change: Get Your Customized Impactful Report Now!
https://www.futuremarketinsights.com/customization-available/rep-gb-11933
Gene Therapy and Oligonucleotide APIs
Synthetic oligonucleotides are being used in gene therapy for inactivating genes that help in propagating the disease. Antisense oligonucleotide APIs are used for disrupting the faulty gene’s transcription.
Also, siRNA could be used for signaling the cell to disrupt faulty mRNA’s translation. Along these lines, Pharmamar, in Jan 2020, signed an agreement with Jazz Pharmaceuticals to sell the API for “lurbinectedin”, one of the late-phase treatments for SCLC (small cell lung cancer) so that the latter could commercialize it.
Key Segments of Global Oligonucleotide API Industry Survey:
Global Oligonucleotide API Industry by API:
- Antisense Oligonucleotides APIs
- Short Interfering RNA (siRNA) APIs
- Phosphorodiamidate Morpholino Oligonucleotides (PMO) APIs
- MiRNA APIs
- Aptamers APIs
- CpG Oligonucleotides APIs
- Others (ON Conjugates (NP), ShRNA, etc.)
Global Oligonucleotide API Industry by Marketing Status:
- Marketed
- Clinical Trials (Clinical Phases)
Global Oligonucleotide API Industry by End User:
- Contract Manufacturing Organizations (CMOs)
- Pharmaceutical Companies
- Biopharmaceutical Companies
- Contract Development & Manufacturing Organizations (CDMOs)
Global Oligonucleotide API Industry by Region:
- North America Oligonucleotide API Industry
- Latin America Oligonucleotide API Market
- Europe Oligonucleotide API Industry
- East Asia Oligonucleotide API Market
- South Asia & Pacific Oligonucleotide API Industry
- Middle East & Africa (MEA) Oligonucleotide API Industry
Uncovering the assumptions made in the study. Ask a Market Research Expert
https://www.futuremarketinsights.com/ask-question/rep-gb-11933
Key Companies Profiled:
- Jazz Pharmaceuticals, Inc.
- Sarepta Therapeutics
- Biogen
- Dynavax Technologies
- Akcea Therapeutics.
- Alnylam Pharmaceuticals, Inc.
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube